164
Views
14
CrossRef citations to date
0
Altmetric
Research Article

Proteomic detection of cancer in asbestosis patients using SELDI-TOF discovered serum protein biomarkers

, , , , , , & show all
Pages 181-191 | Received 01 Jul 2010, Accepted 23 Nov 2010, Published online: 14 Jan 2011
 

Abstract

Objectives: To identify biomarkers for cancer in asbestosis patients.

Methods: SELDI-TOF and CART were used to identify serum biomarker profiles in 35 asbestosis patients who subsequently developed cancer and 35 did not develop cancer.

Results: Three polypeptide peaks (5707.01, 6598.10, and 20,780.70 Da) could predict the development of cancer with 87% sensitivity and 70% specificity. The first two peaks were identified as KIF18A and KIF5A, respectively, and are part of the Kinesin Superfamily of proteins.

Conclusions: We identified two Kinesin proteins that can be potentially used as blood biomarkers to identify asbestosis patients at risk of developing lung cancer.

Acknowledgements

The authors would like to thank the patients who have participated in our research.

Declaration of interest

This work was supported in part by grants from the National Institute for Occupational Safety and Health (R01-OH04192, R01-OH07590) to PWB-R and the National Institute of Environmental and Health Sciences (2 P01 ES011810) to LSN. Dr. Brandt-Rauf is currently on the editorial board of Biomarkers.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.